Journal of Kerman University of Medical Sciences

Assessment of Serum Levels of Phosphate and Corticosterone as Possible Biomarkers for Early Diagnosis of Parkinson’s Disease in Rats with 6-OHDA-Induced Parkinson

Document Type : Original Article

Authors

Hashem Haghdoost-Yazdi 1
Sepideh Nigjeh 2
Seyed Amir Hadi Hosseini 2
Sahar Sharifi 2
Fatemeh Kaveh 3
Hossein Piri 1

1 Cellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran

2 Student Research Committee, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran

3 Department of Cellular Therapy, Institute for Cancer Research, Oslo University Hospital, Norway

https://doi.org/10.34172/jkmu.2024.18
Abstract
Background: Early diagnosis of Parkinson›s disease can play an important role in improving its prognosis. Due to controversies about the serum level of corticosterone and phosphate in parkinsonian rats, this study was designed to measure and evaluate the levels of corticosterone and phosphate as possible biomarkers of early diagnosis in rats with 6-OHDA-induced parkinsonism.
Methods: Forty rats were divided into three groups: control (n = 10), sham (n = 10), and 6-OHDA (n = 20). The rats in the 6-OHDA and sham groups underwent stereotaxic surgery to be injected with 6-OHDA and its carrier into their medial forebrain bundle (MFB). Apomorphine-induced rotational and cylinder tests were done to examine parkinsonism progression and sensory-motor function. Corticosterone and phosphate serum levels were measured in the serum and striatum.
Results: Net contralateral rotations and asymmetry scores in the fourth, sixth, and eighth weeks after surgery compared with the second week showed a gradual increase in the 6-OHDA group. The serum levels of corticosterone were 90 ± 13 before surgery, and they declined to 88 ± 36 and 55 ± 9 ng/L in the second and eighth weeks after surgery, respectively. The serum levels of phosphate were 6 ± 0.22 before surgery, and they decreased to 5.2 ± 0.13 and 5 ± 0.12 mg/dl in the second and eighth weeks after surgery, respectively. The serum levels of phosphate and corticosterone remained relatively unchanged in the sham and control groups.
Conclusion: In conclusion, the progressive death of dopaminergic neurons is accompanied by decreased serum corticosterone and phosphate levels. Thus, the serum level of corticosterone can be used as a biomarker in diagnosing Parkinson’s disease. In contrast, serum phosphate levels were still within the normal range and cannot be used as a biomarker.

Keywords

Parkinson’s disease
Neurodegeneration
Corticosterone
Phosphate
Subjects
  1. Weller J, Budson A. Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Res. 2018;7:F1000 Faculty Rev-1161. doi: 10.12688/f1000research.14506.1.
  2. Grigoruţă M, Martínez-Martínez A, Dagda RY, Dagda RK. Psychological stress phenocopies brain mitochondrial dysfunction and motor deficits as observed in a parkinsonian rat model. Mol Neurobiol. 2020;57(4):1781-98. doi: 10.1007/ s12035-019-01838-9.
  3. Willard AM, Bouchard RS, Gittis AH. Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice. Neuroscience. 2015;301:254- 67. doi: 10.1016/j.neuroscience.2015.05.068.
  4. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. doi: 10.1038/nrdp.2017.13.
  5. Pagan FL. Improving outcomes through early diagnosis of Parkinson’s disease. Am J Manag Care. 2012;18(7 Suppl):S176-82.
  6. Calvani R, Picca A, Landi G, Marini F, Biancolillo A, Coelho-Junior HJ, et al. A novel multi-marker discovery approach identifies new serum biomarkers for Parkinson’s disease in older people: an exosomes in Parkinson disease (EXPAND) ancillary study. Geroscience. 2020;42(5):1323-34. doi: 10.1007/s11357-020-00192-2.
  7. Cagney DN, Sul J, Huang RY, Ligon KL, Wen PY, Alexander BM. The FDA NIH biomarkers, endpoints, and other tools (BEST) resource in neuro-oncology. Neuro Oncol. 2018;20(9):1162-72. doi: 10.1093/neuonc/nox242.
  8. Deumens R, Blokland A, Prickaerts J. Modeling Parkinson’s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol. 2002;175(2):303-17. doi: 10.1006/exnr.2002.7891.
  9. Jin F, Wu Q, Lu YF, Gong QH, Shi JS. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson’s disease in rats. Eur J Pharmacol. 2008;600(1-3):78-82. doi: 10.1016/j. ejphar.2008.10.005.
  10. Haghdoost-Yazdi H, Piri H, Faraji A, Fraidouni N, Dargahi T, Mahmudi M, et al. Pretreatment with potassium channel blockers of 4-aminopyridine and tetraethylammonium attenuates behavioural symptoms of parkinsonism induced by intrastriatal injection of 6-hydroxydopamine; the role of lipid peroxidation. Neurol Res. 2016;38(4):294-300. doi: 10.1080/01616412.2015.1114290.
  11. Razaghi R, Piri H, Jafari H, Rastgoo N, Hosseini MA, Haghdoost-Yazdi H. Evaluation of the association between serum levels of testosterone and prolactin with 6- hydroxydopamine-induced parkinsonism in male rats. Basic Clin Neurosci. 2021;12(4):453-64. doi: 10.32598/ bcn.2021.671.3.
  12. Sofiabadi M, Haghdoost-Yazdi H, Piri H, Esmaeili M. B vitamins supplement potentiates antiparkinsonian effect of flunarizine: the behavioral and biochemical evidences from 6-hydroxydopamine animal model. J Kerman Univ Med Sci. 2018;25(5):414-27. [Persian].
  13. Minaei A, Sarookhani MR, Haghdoost-Yazdi H, Rajaei F. Hydrogen sulfide attenuates induction and prevents progress of the 6-hydroxydopamine-induced parkinsonism in rat through activation of ATP-sensitive potassium channels and suppression of ER stress. Toxicol Appl Pharmacol. 2021;423:115558. doi: 10.1016/j.taap.2021.115558.
  14. Magno LAV, Collodetti M, Tenza-Ferrer H, Romano-Silva MA. Cylinder test to assess sensory-motor function in a mouse model of Parkinson’s disease. Bio Protoc. 2019;9(16):e3337. doi: 10.21769/BioProtoc.3337.
  15. Haghdoost-Yazdi H, Faraji A, Fraidouni N, Movahedi M, Hadibeygi E, Vaezi F. Significant effects of 4-aminopyridine and tetraethylammonium in the treatment of 6-hydroxydopamine-induced Parkinson’s disease. Behav Brain Res. 2011;223(1):70-4. doi: 10.1016/j.bbr.2011.04.021.
  16. Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Prog Neurobiol. 2013;106-107:17-32. doi: 10.1016/j.pneurobio.2013.04.004.
  17. Herman JP, Seroogy K. Hypothalamic-pituitary-adrenal axis, glucocorticoids, and neurologic disease. Neurol Clin. 2006;24(3):461-81i. doi: 10.1016/j.ncl.2006.03.006.
  18. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008;4(11):600-9. doi: 10.1038/ncpneuro0924.
  19. Pacosz J. The Effects of Short-Term Glucocorticoid Exposure on Hippocampal Neuronal Structure and Signaling Pathways in Female Rats [dissertation]. University of Guelph; 2021.
  20. Sobesky JL, D’Angelo HM, Weber MD, Anderson ND, Frank MG, Watkins LR, et al. Glucocorticoids mediate short-term high-fat diet induction of neuroinflammatory priming, the NLRP3 inflammasome, and the danger signal HMGB1. eNeuro. 2016;3(4):ENEURO.0113-16.2016. doi: 10.1523/ eneuro.0113-16.2016.
  21. Vyas S, Rodrigues AJ, Silva JM, Tronche F, Almeida OF, Sousa N, et al. Chronic stress and glucocorticoids: from neuronal plasticity to neurodegeneration. Neural Plast. 2016;2016:6391686. doi: 10.1155/2016/6391686.
  22. Soares NM, Pereira GM, Altmann V, de Almeida RM, Rieder CR. Cortisol levels, motor, cognitive and behavioral symptoms in Parkinson’s disease: a systematic review. J Neural Transm (Vienna). 2019;126(3):219-32. doi: 10.1007/s00702-018- 1947-4.
  23. Sullivan RM, Gratton A. Relationships between stress-induced increases in medial prefrontal cortical dopamine and plasma corticosterone levels in rats: role of cerebral laterality. Neuroscience. 1998;83(1):81-91. doi: 10.1016/ s0306-4522(97)00370-9.
  24. Törnhage CJ, Skogar Ö, Borg A, Larsson B, Robertsson L, Andersson L, et al. Short- and long-term effects of tactile massage on salivary cortisol concentrations in Parkinson’s disease: a randomised controlled pilot study. BMC Complement Altern Med. 2013;13:357. doi: 10.1186/1472- 6882-13-357.
  25. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 2021;20(5):385-97. doi: 10.1016/s1474-4422(21)00030-2.
  26. Djamshidian A, O’Sullivan SS, Papadopoulos A, Bassett P, Shaw K, Averbeck BB, et al. Salivary cortisol levels in Parkinson’s disease and its correlation to risk behaviour. J Neurol Neurosurg Psychiatry. 2011;82(10):1107-11. doi: 10.1136/jnnp.2011.245746.
  27. Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I. Twenty-four hour cortisol release profiles in patients with Alzheimer’s and Parkinson’s disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging. 1997;18(3):285-9. doi: 10.1016/s0197- 4580(97)80309-0.
  28. Mizoguchi K, Ishige A, Takeda S, Aburada M, Tabira T. Endogenous glucocorticoids are essential for maintaining prefrontal cortical cognitive function. J Neurosci. 2004;24(24):5492-9. doi: 10.1523/jneurosci.0086-04.2004.
  29. Barnum CJ, Eskow KL, Dupre K, Blandino P Jr, Deak T, Bishop C. Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin- 1beta. Neuroscience. 2008;156(1):30-41. doi: 10.1016/j. neuroscience.2008.07.016.
  30. Sugama S, Takenouchi T, Kitani H, Fujita M, Hashimoto M. Microglial activation is inhibited by corticosterone in dopaminergic neurodegeneration. J Neuroimmunol. 2009;208(1-2):104-14. doi: 10.1016/j.jneuroim.2009.01.016.
  31. Tentillier N, Etzerodt A, Olesen MN, Rizalar FS, Jacobsen J, Bender D, et al. Anti-inflammatory modulation of microglia via CD163-targeted glucocorticoids protects dopaminergic neurons in the 6-OHDA Parkinson’s disease model. J Neurosci. 2016;36(36):9375-90. doi: 10.1523/jneurosci.1636-16.2016.
  32. Luan H, Liu LF, Tang Z, Zhang M, Chua KK, Song JX, et al. Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson’s disease. Sci Rep. 2015;5:13888. doi: 10.1038/ srep13888.
  33. Håglin L, Bäckman L. Covariation between plasma phosphate and daytime cortisol in early Parkinson’s disease. Brain Behav. 2016;6(12):e00556. doi: 10.1002/brb3.556.
  34. Samavarchi Tehrani S, Sarfi M, Yousefi T, Ahmadi Ahangar A, Gholinia H, Mohseni Ahangar R, et al. Comparison of the calcium-related factors in Parkinson’s disease patients with healthy individuals. Caspian J Intern Med. 2020;11(1):28-33. doi: 10.22088/cjim.11.1.28.
  35. Abou-Raya S, Helmii M, Abou-Raya A. Bone and mineral metabolism in older adults with Parkinson’s disease. Age Ageing. 2009;38(6):675-80. doi: 10.1093/ageing/afp137.
  36. Håglin L. High serum phosphate concentration as the result of smoking might underlie the lower risk of Parkinson’s disease. Med Hypotheses. 2015;85(3):287-90. doi: 10.1016/j. mehy.2015.05.017.
  37. Meamar R, Maracy M, Chitsaz A, Aghaye-Ghazvini MR, Izadi M, Tanhaei AP. Association between serum biochemical levels, related to bone metabolism and Parkinson’s disease. J Res Med Sci. 2013;18(Suppl 1):S39-42.
Journal of Kerman University of Medical Sciences
Volume 31, Issue 3
May and June 2024
Pages 104-112

Home

Editorial Board

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us